Physician profile
Mike Liu
NPI 1225489255
$18,486.68
in general payments reported to CMS, 2019-2025
66 companies · $4,270 in 2025
The $4,270 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $21.35 · 2021: $1,622 · 2022: $3,709 · 2023: $3,868 · 2024: $4,561 · 2025: $4,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $341 · Education: $132 · Honoraria: $22.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,203.94 |
| Travel and Lodging | $341.48 |
| Education | $132.00 |
| Honoraria | $22.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,174.47 | 2021-2025 | |
| Sk Life Science, INC. | $1,826.78 | 2021-2025 | Xcopri |
| Biogen, INC. | $1,233.17 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Ucb, INC. | $970.67 | 2021-2025 | Briviact, Rystiggo |
| Livanova USA, INC. | $954.03 | 2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $913.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $795.57 | 2021-2025 | |
| Eisai INC. | $738.02 | 2021-2025 | |
| Lilly USA, LLC | $712.90 | 2021-2025 | Reyvow, Emgality, Amyvid |
| Argenx US, INC. | $614.20 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $594.54 | 2023-2024 | Aptiom |
| Amgen INC. | $576.72 | 2021-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $510.40 | 2019-2025 | Ultomiris |
| Aucta Pharmaceuticals, INC. | $488.62 | 2024-2025 | Motpoly Xr |
| Genzyme Corporation | $389.15 | 2021-2024 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mike Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.